Get the Stockscreener App
6.435
2.96%
0.185
After Hours:
6.55
0.115
+1.79%
Tempest Therapeutics Inc stock is traded at $6.435, with a volume of 59,607.
It is up +2.96% in the last 24 hours and down -8.59% over the past month.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
See More
Previous Close:
$6.25
Open:
$6.18
24h Volume:
59,607
Relative Volume:
0.54
Market Cap:
$23.70M
Revenue:
-
Net Income/Loss:
$-31.11M
P/E Ratio:
-4.2059
EPS:
-1.53
Net Cash Flow:
$-28.18M
1W Performance:
-3.38%
1M Performance:
-8.59%
6M Performance:
-47.90%
1Y Performance:
-71.71%
1-Day Range:
$6.11
$6.47
1-Week Range:
$6.11
$6.69
52-Week Range:
$5.3495
$28.34
Tempest Therapeutics Inc Stock (TPST) Company Profile
Name
Tempest Therapeutics Inc
Sector
Industry
Phone
415-798-8589
Address
2000 SIERRA POINT PARKWAY, BRISBANE
Compare TPST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TPST
Tempest Therapeutics Inc
|
6.435 | 23.24M | 0 | -31.11M | -28.18M | -1.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-10-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Feb-08-24 | Initiated | Jefferies | Buy |
Tempest Therapeutics Inc Stock (TPST) Latest News
Is Tempest Therapeutics Inc. a good long term investmentSuperior stock growth - Autocar Professional
Tempest Therapeutics Inc. Stock Analysis and ForecastExplosive wealth accumulation - jammulinksnews.com
What analysts say about Tempest Therapeutics Inc. stockBreakout stock performance - jammulinksnews.com
What drives Tempest Therapeutics Inc. stock priceTriple-digit wealth increases - Autocar Professional
Is Tempest Therapeutics Inc. stock a growth or value playSmart High Yield Swing Trades - Newser
Why Tempest Therapeutics Inc. stock attracts strong analyst attentionPrecision Entry Strategy - Newser
How Tempest Therapeutics Inc. stock performs during market volatilityFree Real-Time Trading Opportunities - Newser
What makes Tempest Therapeutics Inc. stock price move sharplyFree Access to Community - Newser
Head-To-Head Contrast: Tempest Therapeutics (NASDAQ:TPST) vs. Relmada Therapeutics (NASDAQ:RLMD) - Defense World
Tempest Therapeutics (NASDAQ:TPST) Trading Up 0.2% – Here’s Why - Defense World
Tempest Therapeutics’ Promising Advances in Liver Cancer Treatment - TipRanks
Tempest Receives Clearance to Proceed with Pivotal Trial of - GlobeNewswire
Millennium Management LLC Acquires Shares of 189,506 Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World
Tempest Therapeutics Secures $4.1M in Direct Offering - TipRanks
SEC Form 424B5 filed by Tempest Therapeutics Inc. - Quantisnow
Form 424B5 Tempest Therapeutics, - StreetInsider
Tempest Therapeutics Announces $4.6 Mln Registered Direct Offering With Institutional Investor - Nasdaq
Tempest Therapeutics (TPST) Announces New Stock Purchase Agreeme - GuruFocus
Tempest Therapeutics ends ATM prospectus with Jefferies By Investing.com - Investing.com Canada
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock - The Manila Times
Tempest Therapeutics, Inc. Announces $4.6 Million Registered Direct Offering of Common Stock - Nasdaq
Tempest Therapeutics announces $4.6 million registered direct offering - Investing.com
Tempest Therapeutics ends ATM prospectus with Jefferies - Investing.com
Tempest Therapeutics Terminates ATM Prospectus Supplement Dated February 6, 2025SEC Filing - MarketScreener
Tempest Therapeutics Raises $4.6M From Single Institutional Investor: Strategic Alternative Process Funded - Stock Titan
Why Circle Internet Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga
Pre-market Movers: KLTO, TPST, PYPD, MOVE... - RTTNews
Tempest Therapeutics Shifts Executives to Consulting Roles - TipRanks
Tempest Therapeutics stock rises on EMA Orphan Drug Designation By Investing.com - Investing.com South Africa
Tempest Therapeutics Inc Stock (TPST) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.32%
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):